Aktieanalyser från populära analyshus

28 Aug 2024 09:37

Xbrane Biopharma Q2 2024: Initial take – stronger sales but higher costs - Redeye

Sprint BioScience Q2: Continuing robust sales and activity - Redeye

Recorded sales improved to SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balance was ...

Lifecare Q2 2024: High activity – initial positive signs from longevity trials - Redeye

Nanexa: NEX-22 Progress, Revaluation and Financing - Emergers

After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of ...

Nekkar: H1 Review – Uncovers Hidden Values - Redeye

Lipigon Q2 2024: Marea Launched - Redeye

Redeye comments on Lipigon's Q2 report 2024. The most significant event since our last update was th...

Lipigon Pharmaceuticals

28 Aug 2024 07:29

Inission: Q2 margin declines, but positives as well - ABG

Inission

27 Aug 2024 16:09

Zoomability: Nytt JV-företag avtalat och registrerat i Kina - Analyst Group

Genom marknadsföringssatsningar, registrerat JV i Kina, ett breddat distributionsnätverk samt godkän...

Zoomability

Analys | Analysguiden

27 Aug 2024 15:32

Prostatype Genomics: Tar steget in i USA - Analysguiden

Mendus: Broad progress across the pipeline - Edison

Mendus’s Q224 results reflect a period of steady progress across its clinical programmes.

Mendus

27 Aug 2024 14:10

Catella: Market activity has bottomed out - ABG

Catella

27 Aug 2024 14:09

Analyst Group kommenterar TCECURs Q2-rapport

TCECUR Sweden AB (”TCECUR” eller ”Koncernen”) har publicerat Koncernens delårsrapport för det andra ...

AcouSort: POC system with integrated acoustofluidic technology - Redeye

XP Chemistries: EU-ansökan in i nästa fas - Mangold Insight Analys

XP Chemistries EU-ansökan till EFSA (European Food Safety Authority) har i slutet av juni passerat f...

Faron Pharmaceuticals H1: Turbulent times behind, promising times ahead - Redeye

Faron Pharmaceuticals

Analys | Carlsquare

27 Aug 2024 10:58

Fable Media: kv2 2024: Rekordkvartal ger uppsida - Carlsquare

Under kv2 2024 levererade Fable Media en nettoomsättning i linje med vår förväntan.

Spago Nanomedical: Tumorad-01 advances and the study is now ready to include the next patient cohort - Redeye

Spago Nanomedical

Analys | Analysguiden

27 Aug 2024 10:04

Flowscape: Längre säljcykler påverkar omsättningen negativt - Analysguiden

Nettoomsättningen sjönk med 11% på årsbasis drivet av längre säljcykler och en övergång till en part...

Loihde: Top- and bottom-line estimates beat - Evli

PMD Solutions: PMD is approaching a cash-positive run rate before 2025 - Redeye

PMD Device Solutions (“PMD”) has consolidated the US acquisition and a combination of cost control a...

Beyond Frames: Two significant game launches in H2 - Redeye

Beyond Frames

27 Aug 2024 07:51

Inission: Cost reductions lag, but book-to-bill improving - ABG

Sales +2%, but EBITA -24% vs. ABGSCe, driven by personnel costs Slower cost reductions than we had t...

Heliospectra: H1 completed with solid order intake, high expectations for H2 - Redeye

Heliospectra

26 Aug 2024 15:35

Luxbright: Betydande orderstock om 17 MSEK och en välfylld kassa - Analyst Group

Luxbright AB (”Luxbright” eller ”Bolaget”) har presenterat en H1-rapport som illustrerar att det kom...

Luxbright

26 Aug 2024 14:40

Green Landscaping Group: Solid organic momentum in a tough market - ABG

Curasight Q2: Strategic progress - Redeye

Redeye updates its view of Curasight following the Q2 report and recent events in the company, inclu...

Curasight

Analys | Analysguiden

26 Aug 2024 09:27

Devport: Andra kvartalet 2024 - Analysguiden

DevPort

26 Aug 2024 09:27

Analyst Groups uppföljning av Embark Groups rapport

Embark Group (f.d. Lucky Games) har publicerat bolagets delårsrapport för det andra kvartalet år 202...

EMB Mission Bound